Bayer's MRI Contrast Agent Gadovist Could Get "Lower-Risk" Designation
This article was originally published in The Pink Sheet Daily
Executive Summary
But the sponsor will have to convince an FDA advisory committee that the drug's unusual dosing will not cause medication errors in a crowded class.
You may also be interested in...
FDA Discourages "Negative Safety Claims" In Labels Even At The Risk Of Inconsistency
FDA does not generally allow any claims in labeling that a safety issue does not exist with the product "because the evidence to support a conclusion of 'no effect' is very difficult to generate," the agency said. It's a policy that some academics say creates confusion, though.
FDA Discourages "Negative Safety Claims" In Labels Even At The Risk Of Inconsistency
FDA does not generally allow any claims in labeling that a safety issue does not exist with the product "because the evidence to support a conclusion of 'no effect' is very difficult to generate," the agency said. It's a policy that some academics say creates confusion, though.
Gadavist Dosing Complexities To Be Handled With Packaging, Not REMS
Bayer's newly approved gadolinium-based contrast agent only needs half the dose of other such products. The label eschews comparative safety claims.